NCT04089735View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

April 7, 2020

Study Completion Date

April 7, 2020

Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
DRUG

APP13007, 0.05%

APP13007 eye drop, 0.05%

DRUG

APP13007, 0.1%

APP13007 eye drop, 0.1%

DRUG

APP13007 Placebo, 0.05%

APP13007 placebo eyedrop, 0.05%

DRUG

APP13007 Placebo, 0.1%

APP13007 placebo eyedrop, 0.1%

Trial Locations (9)

18704

Eye Care Specialists, Kingston

32204

Levenson Eye Associates, Jacksonville

32256

Bowden Eye and Associates, Jacksonville

63131

Ophthalmology Associates, St Louis

78731

Keystone Research Ltd., Austin

79902

Cataract & Glaucoma Center, El Paso

85032

Cornea and Cataract Consultants of Arizona, Phoenix

90301

United Medical Research Institute, Inglewood

95670

Martel Eye Medical Group, Rancho Cordova

Sponsors
All Listed Sponsors
lead

Formosa Pharmaceuticals, Inc.

INDUSTRY